GB201521357D0 - Methods for predicting response to anti-TNF therapy - Google Patents
Methods for predicting response to anti-TNF therapyInfo
- Publication number
- GB201521357D0 GB201521357D0 GBGB1521357.2A GB201521357A GB201521357D0 GB 201521357 D0 GB201521357 D0 GB 201521357D0 GB 201521357 A GB201521357 A GB 201521357A GB 201521357 D0 GB201521357 D0 GB 201521357D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- methods
- predicting response
- tnf therapy
- tnf
- therapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/136—Screening for pharmacological compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Artificial Intelligence (AREA)
- Evolutionary Computation (AREA)
- Software Systems (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Bioethics (AREA)
- Theoretical Computer Science (AREA)
- Signal Processing (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Biomedical Technology (AREA)
- Primary Health Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Priority Applications (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521357.2A GB201521357D0 (en) | 2015-12-03 | 2015-12-03 | Methods for predicting response to anti-TNF therapy |
| CA3005695A CA3005695A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
| CN201680071029.6A CN108291261A (zh) | 2015-12-03 | 2016-12-02 | 用于预测对抗tnf治疗的响应的方法 |
| US15/780,762 US20190367984A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
| JP2018529050A JP2018537100A (ja) | 2015-12-03 | 2016-12-02 | 抗ｔｎｆ療法に対する応答を予測する方法 |
| PCT/GB2016/053798 WO2017093750A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
| AU2016364003A AU2016364003A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-TNF therapy |
| EP16808777.3A EP3384044A1 (en) | 2015-12-03 | 2016-12-02 | Methods for predicting response to anti-tnf therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1521357.2A GB201521357D0 (en) | 2015-12-03 | 2015-12-03 | Methods for predicting response to anti-TNF therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB201521357D0 true GB201521357D0 (en) | 2016-01-20 |
Family
ID=55234362
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB1521357.2A Ceased GB201521357D0 (en) | 2015-12-03 | 2015-12-03 | Methods for predicting response to anti-TNF therapy |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20190367984A1 (enExample) |
| EP (1) | EP3384044A1 (enExample) |
| JP (1) | JP2018537100A (enExample) |
| CN (1) | CN108291261A (enExample) |
| AU (1) | AU2016364003A1 (enExample) |
| CA (1) | CA3005695A1 (enExample) |
| GB (1) | GB201521357D0 (enExample) |
| WO (1) | WO2017093750A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2018113694A (ru) | 2015-09-17 | 2019-10-17 | Эмджен Инк. | Прогноз клинического ответа на антагонисты ил-23 с использованием биомаркеров сигнального пути ил-23 |
| EP3654993A4 (en) * | 2017-07-17 | 2021-08-25 | The Broad Institute, Inc. | CELL ATLAS OF HEALTHY HUMAN COLUMN AND HUMAN COLUMN WITH COLITIS ULCEROSA |
| CN108047327B (zh) * | 2017-11-29 | 2020-08-07 | 中国医学科学院北京协和医院 | 一种检测骨关节炎的生物标志物及其应用 |
| WO2019159186A1 (en) * | 2018-02-19 | 2019-08-22 | Genefron Ltd. | Methods of determining response to tnf alpha blockers |
| EP3765634A4 (en) | 2018-03-16 | 2021-12-01 | Scipher Medicine Corporation | METHODS AND SYSTEMS FOR PREDICTING THE RESPONSE TO ANTI-TNF THERAPIES |
| SG11202104882WA (en) * | 2018-11-15 | 2021-06-29 | Ampel Biosolutions Llc | Machine learning disease prediction and treatment prioritization |
| JP2022541125A (ja) | 2019-06-27 | 2022-09-22 | サイファー メディシン コーポレーション | 患者を層別化するための分類子の開発 |
| CA3152279A1 (en) * | 2019-10-04 | 2021-04-08 | The Regents Of The University Of Michigan | Methods for determining responsiveness to anti-tumor necrosis factor therapy in the treatment of psoriasis |
| CA3199737A1 (en) * | 2020-11-30 | 2022-06-02 | Tobin Dickerson | Microneedle devices and methods, and skin condition assays |
| US20220291238A1 (en) * | 2021-03-12 | 2022-09-15 | Janssen Biotech, Inc. | Methods for Predicting Treatment Response in Ulcerative Colitis |
| CN113373218A (zh) * | 2021-08-04 | 2021-09-10 | 杭州浙大迪迅生物基因工程有限公司 | 一组检测人嗜酸性粒细胞阳离子蛋白mRNA表达的引物组和试剂盒 |
| CN116559453A (zh) * | 2022-11-22 | 2023-08-08 | 杭州广科安德生物科技有限公司 | 一种用于肺癌检测的生物标志物 |
| WO2026047197A1 (en) * | 2024-08-30 | 2026-03-05 | Sanofi Biotechnology | Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2658171A1 (en) * | 2006-07-13 | 2008-01-17 | Source Precision Medicine, Inc. D/B/A Source Mdx | Gene expression profiling for identification, monitoring and treatment of multiple sclerosis |
| WO2008132176A2 (en) * | 2007-04-27 | 2008-11-06 | Universite Catholique De Louvain | Method for evaluating the response of an individual to tnf blocking therapy |
| BRPI0812461A2 (pt) * | 2007-06-08 | 2017-06-13 | Biogen Idec Inc | método de prever a resposta de um indivíduo a uma terapia, método de tratamento de um distúrbio imunológico, composição e kit |
| EP2192197A1 (en) * | 2008-11-27 | 2010-06-02 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Predicting clinical response to treatment with a soluble tnf-antagonist or tnf, or a tnf receptor agonist |
| CN102597268B (zh) * | 2009-09-03 | 2017-09-22 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗、诊断和监控类风湿性关节炎的方法 |
| US20130042333A1 (en) * | 2011-05-06 | 2013-02-14 | Jean-Gabriel JUDDE | Markers for cancer prognosis and therapy and methods of use |
| HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
| US9809854B2 (en) * | 2012-11-15 | 2017-11-07 | New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery | Biomarkers for disease activity and clinical manifestations systemic lupus erythematosus |
-
2015
- 2015-12-03 GB GBGB1521357.2A patent/GB201521357D0/en not_active Ceased
-
2016
- 2016-12-02 EP EP16808777.3A patent/EP3384044A1/en not_active Withdrawn
- 2016-12-02 US US15/780,762 patent/US20190367984A1/en not_active Abandoned
- 2016-12-02 CN CN201680071029.6A patent/CN108291261A/zh active Pending
- 2016-12-02 CA CA3005695A patent/CA3005695A1/en not_active Abandoned
- 2016-12-02 AU AU2016364003A patent/AU2016364003A1/en not_active Abandoned
- 2016-12-02 JP JP2018529050A patent/JP2018537100A/ja active Pending
- 2016-12-02 WO PCT/GB2016/053798 patent/WO2017093750A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| CN108291261A (zh) | 2018-07-17 |
| WO2017093750A1 (en) | 2017-06-08 |
| JP2018537100A (ja) | 2018-12-20 |
| US20190367984A1 (en) | 2019-12-05 |
| AU2016364003A1 (en) | 2018-06-28 |
| CA3005695A1 (en) | 2017-06-08 |
| EP3384044A1 (en) | 2018-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285287B1 (en) | Antibodies to tigit | |
| GB201521357D0 (en) | Methods for predicting response to anti-TNF therapy | |
| IL256499A (en) | Antibodies to CD40 | |
| IL251508A0 (en) | Anti-TNF compounds | |
| FI3198035T3 (fi) | Menetelmiä lääkevasteen ennustamiseksi | |
| GB2538731B (en) | Methods | |
| GB201708360D0 (en) | Methods for determining health risks | |
| GB201410262D0 (en) | Novel method | |
| IL273265A (en) | New combinations for antigen-based therapy | |
| IL251858A0 (en) | Enhanced il-6 antagonists | |
| GB201417341D0 (en) | Chromatography | |
| IL248697A0 (en) | Methods for purifying antibodies | |
| GB201518762D0 (en) | Methods | |
| GB201508927D0 (en) | Methods | |
| SG11201703801SA (en) | Novel methods | |
| SG11201609522TA (en) | Methods for treating cardiovascular diseases | |
| GB201515655D0 (en) | Methods | |
| EP3164122A4 (en) | Predicting response to cancer therapy | |
| GB201411567D0 (en) | Quantification methods | |
| GB201416773D0 (en) | Novel Methods For Including An Imune Response | |
| GB201400309D0 (en) | Predicting Resistance to disease | |
| SG11201608328RA (en) | Method for predicting response to therapy for cancer | |
| GB201512609D0 (en) | Methods | |
| HK1260665A1 (en) | Methods for predicting response to anti-tnf therapy | |
| GB201509493D0 (en) | Therapeutic antibody |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |